Five things for pharma marketers to know: Friday, July 22, 2016


1. Amgen and Allergan said a Phase-III clinical trial for their Herceptin biosimilar met its primary endpoint. Roche's Herceptin is one of the world's best-selling breast-cancer drugs. (WSJ)

2. Roche on Thursday told investors that even though sales of Herceptin, Avastin, and Rituxan — its blockbuster oncology trio — rose, the company plans to launch five new drugs over the next year. (Reuters)

3. The government has filed separate lawsuits to block a pair of insurance deals: the mergers of Aetna and Humana and of Anthem and Cigna. Consumer groups raised questions about whether the deals will mean higher costs and less access for patients. (NYT)

4. Novo Nordisk cosponsored a panel about obesity at the Republican National Convention in Cleveland and plans to do the same at another event during the Democratic Convention in Philadelphia. The effort focuses on encouraging lawmakers to lift a ban on Medicare reimbursement of obesity drugs. (Stat)

5. Valeant Pharmaceuticals received a complete response letter from the FDA about how an eye drop product is manufactured. (Reuters)